PRODUCT INFORMATION



Cevipabulin

Item No. 33224

CAS Registry No.: 849550-05-6

Formal Name: 5-chloro-6-[2,6-difluoro-4-[3-(methylamino)propoxy]

phenyl]-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-[1,2,4]

triazolo[1,5-a]pyrimidin-7-amine

Synonym: TTI-237

MF: $C_{18}H_{18}CIF_5N_6O$

FW: 464.8 **Purity:**

UV/Vis.: λ_{max} : 224, 297 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cevipabulin is supplied as a crystalline solid. A stock solution may be made by dissolving the cevipabulin in the solvent of choice, which should be purged with an inert gas. Cevipabulin is soluble in the organic solvent DMSO.

Description

Cevipabulin is an activator of microtubule polymerization. 1.2 It induces aggregation of isolated bovine brain tubulin in a concentration-dependent manner. Cevipabulin (100 µM) inhibits binding of vinblastine (Item No. 11762), but not colchicine (Item No. 9000760), to tubulin in cell-free assays. It induces mitotic block in HeLa cells when used at a concentration of 68 nM and is cytotoxic to MDA-MB-468, MDA-MB-435, LNCaP, SKOV3, and HeLa cancer cell lines (IC_{50} S = 18-40 nM). Cevipabulin (20 mg/kg, i.v.) reduces tumor growth in a LoVo colon adenocarcinoma mouse xenograft model.

References

- 1. Beyer, C.F., Zhang, N., Hernandez, R., et al. TTI-237: A novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 68(7), 2292-2300 (2008).
- Beyer, C.F., Zhang, N., Hernandez, R., et al. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother. Pharmacol. 64(4), 681-689 (2009).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM